WASHINGTON — An experimental treatment for genital herpes suppresses the viral infection better than the primary drug now used, a study shows. But whether the new compound will reach the market may depend on the resolution of a recent disconcerting finding of anemia in animals getting the drug candidate in separate tests.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.